THE ADVENT OF CRISPR Cas9 – NEW GENERATION OF GENOME EDITING TOOLS (A REVIEW)

PDF

Published: 2020-02-17

Page: 74-82


NAVDEEP SINGH

School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, India.

MAHENDRA PRATAP SINGH *

School of Bioengineering and Biosciences, Lovely Professional University, Phagwara, India.

*Author to whom correspondence should be addressed.


Abstract

The prokaryotes possess clustered repeated interspaced short palindromic repeat system (CRISPR), which forms the basis of acquired immunity of single celled organisms against the viral threats. This system works along with the Cas9 enzyme, basically a restriction endonuclease to cleave the sequences at a targeted site complementary to CRISPR. The Cas9 endonuclease can be programmed and is regulated by small guide RNA (siRNA) sequences of about 20 bases long that cleave the DNA at site-specific regions causing mutations. These small guide RNA can be designed to cleave at particular loci, the guide RNA contains complementary base sequence to that of the DNA of our interest, therefore this property of RNA makes CRISPR more efficient tool as the RNA will bind only to the opposite base pairs none other part of DNA. Presently, various experiments on gene engineering, mutagenesis, gene expression are being conducted on various organisms and it is now believed that CRISPR can be used to treat single faulty gene diseases to turn a gene on or shut off and using animals models to study the genetically inherited diseases of humans. This review article will provide new insight on the advancements and applications of CRISPR Cas9 technology.

Keywords: CRISPR, endonuclease, genetic engineering, siRNA, Cas9.


How to Cite

SINGH, N., & SINGH, M. P. (2020). THE ADVENT OF CRISPR Cas9 – NEW GENERATION OF GENOME EDITING TOOLS (A REVIEW). PLANT CELL BIOTECHNOLOGY AND MOLECULAR BIOLOGY, 21(3-4), 74–82. Retrieved from https://ikprress.org/index.php/PCBMB/article/view/4941

Downloads

Download data is not yet available.

References

Ran F, Ann et al. Genome engineering using the CRISPR-Cas9 system. Nature Protocols. 2013;8:11-22,81.

Doudna Jennifer A, Emmanuelle Charpentier. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346:6213-1258096.

Jinkerson Robert E, Martin C. Jonikas. Molecular techniques to interrogate and edit the Chlamydomonas nuclear genome. The Plant Journal. 2015;82(3): 393-412.

Mans Robert, et al. CRISPR/Cas9: A molecular Swiss army knife for simultaneous introduction of multiple genetic modifications in Saccharomyces cerevisiae. FEMS Yeast Research. 2015; 15(2).

Niu Jingwen, Bin Zhang, Hu Chen. Applications of TALENs and CRISPR/Cas9 in human cells and their potentials for gene therapy. Molecular Biotechnology. 2014;56(8):681-688.

Rodríguez-Rodríguez Diana Raquel et al. Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases (Review). International Journal of Molecular Medicine. 2019;43(4): 1559-1574.
DOI: 10.3892/ijmm.2019.4112

Barakate Abdellah, Jennifer Stephens. An overview of CRISPR-based tools and their improvements: New opportunities in understanding plant–pathogen interactions for better crop protection. Frontiers in Plant Science. 2016;7:765.

Martin Francisco, et al. Biased and unbiased methods for the detection of off-target cleavage by CRISPR/Cas9: An overview. International Journal of Molecular Sciences. 2016;17(9):1507.

Cong Le, et al. Multiplex genome engineering using CRISPR/Cas systems. Science. 2013;339(6121):819-823.

Ding Qiurong, et al. A TALEN genome-editing system for generating human stem cell-based disease models. Cell Stem Cell. 2013;12(2):238-251.

Ledford Heidi. CRISPR, the disruptor. Nature News. 2015;522(7554):20.

Evitt Niklaus H, Shamik Mascharak, Russ B. Altman. Human germline CRISPR-Cas modification: Toward a regulatory framework. The American Journal of Bioethics. 2015;15(12):25-29.

Cyranoski, David. CRISPR gene-editing tested in a person for the first time. Nature New. 2016;539(7630):479.

Cyranoski David. Chinese scientists to pioneer first human CRISPR trial. Nature News. 2016;535(7613):476.

Van der Oost John, et al. CRISPR-based adaptive and heritable immunity in prokaryotes. Trends in Biochemical Sciences. 2009;34(8):401-407.

Zhang Jing, et al. Structure and mechanism of the CMR complex for CRISPR-mediated antiviral immunity. Molecular Cell. 2012; 45(3):303-313.

Ma Xingliang, et al. CRISPR/Cas9 platforms for genome editing in plants: Developments and applications. Molecular Plant. 2016;9(7):961-974.

Jinek Martin, et al. A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. Science. 2012; 337(6096):816-821.

Mali Prashant, et al. RNA-guided human genome engineering via Cas9. Science. 2013;339:823-6.
DOI: 10.1126/science.1232033
Available:https://www.yourgenome.org/facts/what-is-crispr-cas9

Amitai Gil, Rotem Sorek. CRISPR–Cas adaptation: Insights into the mechanism of action. Nature Reviews Microbiology. 2016;14(2):67.

Stern Adi, et al. Self-targeting by CRISPR: Gene regulation or autoimmunity? Trends in Genetics. 2010;26(8):335-340.

Hille Frank, Emmanuelle Charpentier. CRISPR-Cas: Biology, mechanisms and relevance. Philosophical Transactions of the Royal Society B: Biological Sciences. 2016;371(1707):20150496.

Peters Jason M, et al. Bacterial CRISPR: Accomplishments and prospects. Current Opinion in Microbiology. 2015;27:121-126.

Sander Jeffry D, Keith Joung J. CRISPR-Cas systems for editing, regulating and targeting genomes. Nature Biotechnology. 2014;32(4):347.

Zhang Feng, Yan Wen, Xiong Guo. CRISPR/Cas9 for genome editing: progress, implications and challenges. Human Molecular Genetics. 2014;23(R1): R40-R46.
Available:https://ghr.nlm.nih.gov/primer/genomicresearch/genomeediting

Ran F. Ann et al. Genome engineering using the CRISPR-Cas9 system. Nature Protocols. 2013;8(11):2281-2308.
DOI: 10.1038/nprot.2013.143

Ding Qiurong, et al. Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circulation Research. 2014;115(5): 488-492.

Barrangou Rodolphe, Andrew P. May. Unraveling the potential of CRISPR-Cas9 for gene therapy. Expert Opin Biol Ther. 2015;311-314.

Savic Nataša, Gerald Schwank. Advances in therapeutic CRISPR/Cas9 genome editing. Translational Research. 2016;168: 15-21.

Ni Wei, et al. Efficient gene knockout in goats using CRISPR/Cas9 system. PLoS One. 2014;9(9):e106718.

Richter Corinna et al. Function and regulation of clustered regularly interspaced short palindromic repeats (CRISPR) / CRISPR associated (Cas) systems. Viruses. 2012;4(10):2291-311.
DOI: 10.3390/v4102291

Arora Leena, Alka Narula. Gene editing and crop improvement using CRISPR-Cas9 system. Frontiers in Plant Science. 2017;8: 1932.
DOI: 10.3389/fpls.2017.01932

Bortesi Luisa, Rainer Fischer. The CRISPR/Cas9 system for plant genome editing and beyond. Biotechnology Advances. 2015;33(1):41-52.

Dominguez Antonia A, Wendell A. Lim, Lei S. Qi. Beyond editing: Repurposing CRISPR–Cas9 for precision genome regulation and interrogation. Nature reviews Molecular Cell Biology. 2016; 17(1):5.

Sternberg Samuel H, Jennifer A. Doudna. Expanding the biologist’s toolkit with CRISPR-Cas9. Molecular Cell. 2015;58(4): 568-574.

Bikard David, Luciano A. Marraffini. Control of gene expression by CRISPR-Cas systems. F1000 Prime Reports. 2013;5:47.
DOI: 10.12703/P5-47

Baliou Stella, et al. CRISPR therapeutic tools for complex genetic disorders and cancer (Review). International Journal of Oncology. 2018;53(2):443-468.
DOI: 10.3892/ijo.2018.4434

Luo Michelle L, et al. Current and future prospects for CRISPR-based tools in bacteria. Biotechnology and Bioengineering. 2016;113(5):930-43.
DOI: 10.1002/bit.25851

Xue HY, et al. In vivo gene therapy potentials of CRISPR-Cas9. 2016;557.

Gori Jennifer L, et al. Delivery and specificity of CRISPR/Cas9 genome editing technologies for human gene therapy. Human Gene Therapy. 2015;26(7):443-451.

Miller A. Dusty. Human gene therapy comes of age. Nature. 1992;357(6378): 455.

Katrekar Dhruva, Michael Hu, Prashant Mali. Advances in CRISPR-Cas based genome engineering. Current Opinion in Biomedical Engineering. 2017;1:78-86.

Dai Wei-Jing, et al. CRISPR-Cas9 for in vivo gene therapy: Promise and hurdles. Molecular Therapy-Nucleic Acids. 2016; 5:e349.

Tu Zhuchi, et al. CRISPR/Cas9: A powerful genetic engineering tool for establishing large animal models of neurodegenerative diseases. Molecular Neurodegeneration. 2015;10(1):1-8.

Giau Vo Van et al. Genome-editing applications of CRISPR-Cas9 to promote in vitro studies of Alzheimer's disease. Clinical Interventions in Aging. 2018;13: 221-233.
DOI: 10.2147/CIA.S155145

Liu Xuejun, et al. CRISPR/Cas9-mediated genome editing in plants. Methods. 2017; 121:94-102.

Walsh Ryan M, Konrad Hochedlinger. A variant CRISPR-Cas9 system adds versatility to genome engineering. Proceedings of the National Academy of Sciences. 2013;110(39):15514-15515.

Walsh Ryan M, Konrad Hochedlinger. A variant CRISPR-Cas9 system adds versatility to genome engineering. Proceedings of the National Academy of Sciences. 2013;110(39):15514-15515.

White Martyn K, Kamel Khalili. CRISPR/Cas9 and cancer targets: Future possibilities and present challenges. Oncotarget. 2016;7(11):12305-17.
DOI: 10.18632/oncotarget.7104

Liu Chang, et al. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications. Journal of Controlled Release. 2017;266:17-26.

Yang Weili, et al. CRISPR/Cas9: Implications for modeling and therapy of neurodegenerative diseases. Frontiers in Molecular Neuroscience. 2016;9:30.

Lino Christopher A, et al. Delivering CRISPR: A review of the challenges and approaches. Drug Delivery. 2018;25(1): 1234-1257.

Li Ling, et al. Challenges in CRISPR/CAS9 delivery: Potential roles of nonviral vectors. Human Gene Therapy. 2015;26(7):452-462.

Wade Mark. High-throughput silencing using the CRISPR-Cas9 system: A review of the benefits and challenges. Journal of Biomolecular Screening. 2015;20(8):1027-1039.